The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://sauljbzr006660.yourkwikimage.com/2004178/retatrutide_vs_tirzepatide_a_comparative_analysis